Medina Manuel Hidalgo Sells 1,250 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $107.09, for a total transaction of $133,862.50. Following the completion of the transaction, the director directly owned 1,639 shares in the company, valued at $175,520.51. This represents a 43.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00.

Guardant Health Stock Up 0.8%

Shares of NASDAQ GH opened at $118.95 on Friday. The firm’s 50-day moving average price is $91.15 and its two-hundred day moving average price is $98.94. Guardant Health, Inc. has a 52-week low of $36.36 and a 52-week high of $121.01. The stock has a market capitalization of $15.77 billion, a P/E ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter in the prior year, the company earned ($0.62) earnings per share. The firm’s revenue was up 39.4% compared to the same quarter last year. As a group, equities research analysts expect that Guardant Health, Inc. will post -2.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP boosted its stake in Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock worth $53,000 after purchasing an additional 138 shares during the period. Eastern Bank boosted its stake in Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after purchasing an additional 139 shares during the period. First Pacific Financial boosted its stake in Guardant Health by 33.1% in the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after purchasing an additional 139 shares during the period. TD Waterhouse Canada Inc. boosted its stake in Guardant Health by 3.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after purchasing an additional 151 shares during the period. Finally, Xponance LLC boosted its stake in Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after purchasing an additional 199 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Wells Fargo & Company lifted their price target on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, February 20th. UBS Group reaffirmed a “buy” rating and set a $175.00 price target on shares of Guardant Health in a report on Friday, January 30th. Guggenheim lifted their price target on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Leerink Partners lifted their price target on Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $129.00.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.